DrugPatentWatch Database Preview
Intercept Pharms Inc Company Profile
Email this page to a colleague
» See Plans and PricingWhat is the competitive landscape for INTERCEPT PHARMS INC, and what generic alternatives to INTERCEPT PHARMS INC drugs are available?
INTERCEPT PHARMS INC has one approved drug.
There are seven US patents protecting INTERCEPT PHARMS INC drugs.
There are one hundred and three patent family members on INTERCEPT PHARMS INC drugs in thirty-three countries and twelve supplementary protection certificates in eleven countries.
Summary for Intercept Pharms Inc
| International Patents: | 103 |
| US Patents: | 7 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for Intercept Pharms Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Intercept Pharms Inc | OCALIVA | obeticholic acid | TABLET;ORAL | 207999-001 | May 27, 2016 | RX | Yes | No | 10,174,073 | Start Trial | Y | Start Trial | |||
| Intercept Pharms Inc | OCALIVA | obeticholic acid | TABLET;ORAL | 207999-002 | May 27, 2016 | RX | Yes | Yes | 10,052,337 | Start Trial | Y | Start Trial | |||
| Intercept Pharms Inc | OCALIVA | obeticholic acid | TABLET;ORAL | 207999-002 | May 27, 2016 | RX | Yes | Yes | 10,174,073 | Start Trial | Y | Start Trial | |||
| Intercept Pharms Inc | OCALIVA | obeticholic acid | TABLET;ORAL | 207999-002 | May 27, 2016 | RX | Yes | Yes | 7,138,390 | Start Trial | Y | Y | Start Trial | ||
| Intercept Pharms Inc | OCALIVA | obeticholic acid | TABLET;ORAL | 207999-002 | May 27, 2016 | RX | Yes | Yes | Start Trial | Start Trial | |||||
| Intercept Pharms Inc | OCALIVA | obeticholic acid | TABLET;ORAL | 207999-001 | May 27, 2016 | RX | Yes | No | 7,138,390 | Start Trial | Y | Y | Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Intercept Pharms Inc Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Philippines | 12018501318 | Start Trial |
| South Korea | 20170140325 | Start Trial |
| South Korea | 20180095070 | Start Trial |
| South Korea | 20190121871 | Start Trial |
| European Patent Office | 3288958 | Start Trial |
| Philippines | 12014502835 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Intercept Pharms Inc Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1392714 | CR 2017 00025 | Denmark | Start Trial | PRODUCT NAME: OBETICHOLIC ACID; REG. NO/DATE: EU/1/16/1139 20161215 |
| 1392714 | LUC00018 | Luxembourg | Start Trial | PRODUCT NAME: ACIDE OBETICHOLIQUE ET SES DERIVES PHARMACEUTIQUEMENT ACCEPTABLES (OCALIVA); AUTHORISATION NUMBER AND DATE: EU/1/16/1139 20161215 |
| 1392714 | 132017000061826 | Italy | Start Trial | PRODUCT NAME: ACIDO OBETICOLICO(OCALIVA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/16/1139, 20161215 |
| 1392714 | 2017/019 | Ireland | Start Trial | PRODUCT NAME: OBETICHOLIC ACID; REGISTRATION NO/DATE: EU/1/16/1139/001 EU/1/16/1139/002 20161212 |
| 1392714 | 23/2017 | Austria | Start Trial | PRODUCT NAME: OBETICHOLSAEURE, DESSEN PHARMAZEUTISCH AKZEPTABLEN SALZE, SOLVATE ODER AMINOSAEURE-KONJUGATE; REGISTRATION NO/DATE: EU/1/16/1139 20161212 |
| 1392714 | CA 2017 00025 | Denmark | Start Trial | PRODUCT NAME: OBETICHOLIC ACID; REG. NO/DATE: EU/1/16/1139 20161215 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
